drugset / Trial / NCT01318265

Effect of Ketoconazole on Regorafenib (BAY73-4506) Pharmacokinetics

NCT01318265

Phase 1 Completed 24 enrolled Bayer
Non-randomizedCrossoverOpen-label

Summary

The purpose of this study is to estimate the effect of multiple doses of ketoconazole on the pharmacokinetics of a single dose of BAY73-4506 in healthy male volunteers.

Timeline

Start
2011-03
Primary completion
2011-07
Completion
2011-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketoconazole Small molecule 400 mg
Subject Regorafenib Small molecule 160 mg Oral

Indications

No indication recorded.